0001415889-23-010288.txt : 20230623
0001415889-23-010288.hdr.sgml : 20230623
20230623200033
ACCESSION NUMBER: 0001415889-23-010288
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230622
FILED AS OF DATE: 20230623
DATE AS OF CHANGE: 20230623
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KOVEN ANDREW I
CENTRAL INDEX KEY: 0001258673
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38150
FILM NUMBER: 231039212
MAIL ADDRESS:
STREET 1: 3 COLUMBUS CIRCLE, SUITE 1710
STREET 2: C/O ARALEZ PHARMACEUTICALS INC.
CITY: NEW YORK
STATE: NY
ZIP: 10019
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kala Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001479419
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 270604595
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1167 MASSACHUSETTS AVENUE
CITY: ARLINGTON
STATE: MA
ZIP: 02476
BUSINESS PHONE: 781-996-5252
MAIL ADDRESS:
STREET 1: 1167 MASSACHUSETTS AVENUE
CITY: ARLINGTON
STATE: MA
ZIP: 02476
4
1
form4-06232023_080619.xml
X0407
4
2023-06-22
0001479419
Kala Pharmaceuticals, Inc.
KALA
0001258673
KOVEN ANDREW I
C/O KALA PHARMACEUTICALS, INC.
1167 MASSACHUSETTS AVENUE
ARLINGTON
MA
02476
true
false
false
false
0
Common Stock
2023-06-22
4
A
0
7515
0
A
10772
D
Common Stock
2023-06-22
4
A
0
1400
0
A
12172
D
Stock Option (right to buy)
14.56
2023-06-22
4
A
0
10020
0
A
2033-06-21
Common Stock
10020
10020
D
Stock Option (right to buy)
14.56
2023-06-22
4
A
0
3150
0
A
2033-06-21
Common Stock
3150
3150
D
Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026.
Includes 10,772 unvested RSUs.
Grant of RSUs under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023.
Includes 12,172 unvested RSUs.
This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter.
This option was granted on June 22, 2023 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023.
/s/ Mary Reumuth, Attorney-in-Fact
2023-06-23